论文部分内容阅读
本文研究淋巴细胞转染体的产生和转染体单克隆抗体的抗原结合特性．以小鼠宫颈癌细胞系Ｕ１４为抗原免疫小鼠。以制备的Ｕ１４和小鼠骨髓瘤细胞系Ｓｐ２／０ＤＮＡ分别转染经Ｕ１４免疫的小鼠原代脾细胞．将所形成的转染体细胞进行克隆，建成２株淋巴细胞转染体细胞系ＵＤ和ＳＤ．它们能连续生长于含血清和无血清培养液中，但不能在同基因小鼠体内生长．ＵＤ和ＳＤ细胞系所产生的单克隆抗体不仅能与小鼠宫颈癌细胞表面抗原及其可溶性抗原发生特异反应，且能识别人宫颈癌组织和宫颈癌病人血清中的肿瘤抗原决定簇．本实验结果进一步证明了我们提出的肿瘤＂进化抗原＂理论，并提示瘤细胞ＤＮＡ转染造成的淋巴细胞永生化，可能是产生人源性单克隆抗体具有前景的途径．
This article studies the production of lymphocyte transfectants and the antigen-binding properties of transfectant monoclonal antibodies. Mouse cervical cancer cell line U14 was used as antigen to immunize mice. The prepared primary mouse splenocytes immunized with U14 were transfected with the prepared U14 and mouse myeloma cell line Sp2 / 0 DNA, respectively. The resulting transfectant cells were cloned and two lymphocyte transfectant cell lines, UD and SD, were constructed. They can be continuously grown in serum-containing and serum-free medium but not in syngeneic mice. Monoclonal antibodies produced by UD and SD cell lines not only react specifically with mouse cervical cancer cell surface antigens and their soluble antigens, but also recognize tumor epitopes in the serum of human cervical cancer and cervical cancer patients. The results of this experiment further prove our proposed theory of “evolutionary antigen” and suggest that immortalization of lymphocytes by DNA transfection of tumor cells may be a promising pathway for the production of human monoclonal antibodies.